The AIM-listed medical polymer group behind Elast-Eon reported its first period of positive adjusted EBITDA in interim results, alongside a spin-out of its heart-valve unit that reshapes theBalance Sheetahead of a targeted return to net profit.
LSE-listed Creo Medical grew first-half 2026 revenue 45% to £3.2m and cut underlying operating costs 15%, narrowing losses, after outsourcingManufacturingand raising £5.5m. A near-term sale of its European joint venture and going-concern caveats remain live issues.
The Cambridge-based LSE biotech has signed a clinical supply agreement worth a seven-figure sum with a cancer immunotherapy developer, arriving alongside full-year results that show revenue up 81% but losses widening as it builds out manufacturing capacity.
New BEXMAB trial data show frontline blood-cancer patients living longer on Faron's antibody bexmarilimab, but a going-concern warning, a discounted rights issue and a regulator fine complicate theInvestmentcase.
The LSE-listed veterinary group has delivered double-digit revenue growth and profit gains for the year to March 2026, while its first proprietary vaccine, ECOVAXXIN MS, goes on sale across Europe—a milestone two decades in the making.
LSE-listed Poolbeg Pharma has dosed its first patient in a six-site NHS trial of POLB 001, an oral drug designed to prevent cytokine release syndrome in cancer immunotherapy. The company puts the addressable market above $10 billion, with interim data due this summer.
LSE-listed consumer self-care group Venture Life has completed a deal worth up to $28 million for two US intimate-health brands, marking its first materialAcquisitionon American soil since its recent run of UK and European deal-making.
Weeks after winning FDA Fast Track status for its lead melanomaVaccine, LSE-listed Scancell has agreed an all-shareReverse mergerwith Nasdaq-listed Neuphoria Therapeutics, paired with an $89 million financing package to fund a pivotal Phase 3 trial.
The LSE-listed diagnostics group reported broadly flat first-half revenue but wider gross margins and continued cash generation, while pressing on with an on-market share buyback funded from a debt-freeBalance Sheet. Here is what the verified numbers actually show, and what investors should watch next.
Wound-care specialist AOTI Inc says a proposed US Medicare coverage decision for its topical oxygen therapy could unlock a market 65 times larger than today's, as half-year revenue rose to roughly $35 million despite the planned exit from Arizona Medicaid.